Contact
searchSearch
HMP Global

Interventional Oncology News

News
Medicare Updates to Reshape Interventional Oncology Reimbursement in 2026
11/11/2025
Laura Simson, MA
11/11/2025
Vascular Disease Management
Liquid Embolics
Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System
08/07/2025
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025...
08/07/2025
Vascular Disease Management
Embolization
Embolx Launches Sniper G3: Revolutionizing Embolization With Enhanced Efficiency, Ease of Use, and Extended Shelf Life
07/28/2025
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
SUNNYVALE, Calif., July 28, 2025...
07/28/2025
Vascular Disease Management
Embolotherapy
Instylla Completes Submission of Premarket Approval Application for Embrace™ Hydrogel Embolic System
03/11/2025
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025...
03/11/2025
Vascular Disease Management
Embolotherapy
Instylla Announces FDA Clearance of Tembo™ Embolic System
01/29/2025
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
Instylla, Inc., a privately held...
01/29/2025
Vascular Disease Management
News
Novel Endovascular Robotic Surgical System Reaches Midpoint of Pivotal Clinical Trial
09/20/2024
Allison Casey
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY®...
09/20/2024
Vascular Disease Management
News
Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors
09/04/2024
Allison Casey
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the...
09/04/2024
Vascular Disease Management
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
Allison Casey
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Vascular Disease Management
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
Allison Casey
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
Vascular Disease Management
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
Allison Casey
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Cardiovascular Scientific Forum
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
02/03/2026
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration...
02/03/2026
Vascular Disease Management
thrombectomy
Penumbra Launches Lightning Flash 3.0 — The Next Evolution in CAVT Technology
01/27/2026
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the...
01/27/2026
Cath Lab Digest
Acquisitions
Boston Scientific Announces Agreement to Acquire Penumbra, Inc.
01/15/2026
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA,...
01/15/2026
Cath Lab Digest
Peripheral Arterial Disease
CIS and Terrebonne General Are First in Louisiana to Use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter
01/09/2026
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA...
01/09/2026
Vascular Disease Management
Radiation Safety
Rampart Launches SECURE Clinical Program to Advance Clinical Evidence for Next Generation Radiation Protection
01/08/2026
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind,...
01/08/2026
Vascular Disease Management
Deep Venous Disease
Gore Gains FDA Approval for First Deep Venous Stent Indicated for the IVC and Iliofemoral Veins
01/06/2026
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients. FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA...
01/06/2026
Vascular Disease Management
Neuro Intervention
Penumbra Receives CE Mark for MIDWAY and ACCESS25 Delivery Catheters in Europe
12/19/2025
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery...
12/19/2025
Vascular Disease Management
Thrombectomy
Study Finds CAVT (Computer-Assisted Vacuum Thrombectomy) Shortens Hospital Stay and May Ease Burden on Hospital Systems
12/16/2025
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs. 
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs. 
The research suggests that CAVT,...
12/16/2025
Cath Lab Digest
Intravascular Imaging
Philips Agrees to Acquire SpectraWAVE Inc., Advancing Next-Generation Coronary Intravascular Imaging and Physiological Assessment With AI
12/16/2025
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s...
12/16/2025
Vascular Disease Management
Acute Type A Dissection
Gore Announces First Patient Implant of the GORE® Ascending Stent Graft for Treatment of Acute Type A Dissection in ARISE III Pivotal Study
12/15/2025
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant...
12/15/2025
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use